Ed Kaye, a pediatric neurologist, is the chief executive officer and a director of Stoke Therapeutics. Ed previously served as CEO of Sarepta Therapeutics, where he led the successful push to win FDA approval of Exondys 51, a pioneering drug for Duchenne muscular dystrophy. Before taking on the CEO role at Sarepta, he served as the company’s chief medical officer for six years, leading the drive to develop Exondys 51. He also served on Sarepta’s board of directors. Earlier in his career, Ed spent 10 years at Genzyme Corporation, most recently as group vice president of clinical development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. At Genzyme, Ed also held various roles, including vice president of medical affairs for lysosomal storage diseases, vice president of clinical research and interim head of PGH global medical affairs.
Ed currently serves as a member of the boards of directors at Cytokinetics, Inc., Avidity Biosciences and the Massachusetts Biotechnology Council. Prior to entering the biotech industry, Ed trained in pediatrics, pediatric neurology and biochemical genetics. He was on the research staff at Massachusetts General Hospital and Tufts University Medical Center and was the chief of biochemical genetics at the Children’s Hospital of Philadelphia. He was on the pediatric neurology staff at Boston Children’s Hospital until 2021. Ed earned his B.S. in biology from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.
Ed Kaye has shepherded seven new medicines to market for patients with severe genetic diseases. His OTS interview reflects on his days as a biochemical geneticist and pediatric neurologist, and the early mentors who helped shape his career.
Not many people have directly cared for patients and then developed medicines to treat their disease. In this interview, CEO Ed Kaye shares things he wished he knew before he became a doctor, and how it has influenced his decisions as a biotech leader.
In 2023, Dr. Kaye was honored by the Massachusetts Health Council as a Champion of Health for his commitment to fostering a strong culture of health in the state of Massachusetts.
After decades of work in biotech, Stoke CEO Edward M. Kaye, MD remains passionate about developing innovative new medicines.
Dr. Kaye has been recognized by Fierce Pharma as one of the Most Influential People in Biopharma for improving the lives of tens of thousands of people living with severe diseases during his career.
In 2023, Dr. Kaye discussed his contributions to the development of a gene therapy for Duchenne muscular dystrophy with STAT News.
Ed Kaye shared his thoughts about the March 2023 FDA approval of omaveloxolone, the first medicine to treat Friedreich’s Ataxia, and what is means for the rare disease community.
Stoke CEO Edward M. Kaye, M.D. recognized by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences.
Ed Kaye wrote this article for STAT in response to a decline in biotech stock indices, looking to the past for context, and to the future as a source of optimism.
CEO Edward Kaye spoke with BioSpace reporter Gail Dutton about the RNA Renaissance and potential for Stoke to take it in a new direction by upregulating protein expression.
In 2021, Ed Kaye was named in Endpoints News' Legacies, a special feature highlighting 60 biopharma pioneers over 60 who helped birth a tech revolution in the making.
